Académique Documents
Professionnel Documents
Culture Documents
Pfizer Inc.
Company Structure Key Products
Aricept Caduet Celebrex Chantix Detrol/LA Effexor Enbrel Lipitor Lyrica Norvasc Spiriva Viagra Xalatan/Xalacom Zoloft Zyvox
Chairman of the Board & CEO: Ian Read CFO & Executive VP - Business Operations: Frank DAmelio President of Worldwide R&D: Mikael Dolsten Executive VP, Chief Compliance & Risk Officer: Douglas Lankler Executive VP Worldwide Human Resources: Charles Hill Executive VP, CMO: Freda Lewis-Hall Executive VP Worldwide Business Development & Innovation: Kristin Peck
Company Location
Acid-Test Ratio
0.4
0.3
The Current Ratio trend is steady, and in year 2011, Pfizer had $2.06 in current assets for every $1 in shortterm debt.
The Acid-Test trend is positive, and in year 2011, Pfizer had $0.61 in cash & accounts receivable per $1 in current debt.
Inventory Turnover
0.25
0.2 0.15 0.1
1.5
The Total Asset trend is positive, and in 2011, Pfizer generated $0.36 in sales per dollar of assets.
The Inventory Turnover trend is steady, and in 2011, Pfizer moved its inventory 1.94 times.
The Debt Ratio trend is positive, and in 2011, Pfizer financed 21% of its assets with debt.
Pfizer Inc. reported no interest expense for 2009-2011. Therefore interest expense does not affect operating profits.
Price/Earnings Ratio
12%
17.00
10%
16.80
8%
16.60
6%
16.40
4%
16.20
2%
16.00
The Return on Equity trend is positive, and in 2011, Pfizers shareholders received 12% returns on their investments.
The Price/Earnings trend is negative, and in 2011, Pfizers investors were willing to pay $16.33 for $1 of reported earnings.